343. T LYMPHOCYTE SUBSETS CHARACTERISTICS IN DIFFERENT CURATIVE EFFICACY OF NEOADJUVANT THERAPY FOR PATIENTS WITH ESOPHAGEAL SQUAMOUS CELL CARCINOMAXin Nie, Shuya He, Wenwu He, Zhiyu Li, Changding Li, Kunhan Ni, Xuefeng Leng, Yongtao Han, Chenghao Wang
- General Medicine
In patients with resectable esophageal squamous cell carcinoma(ESCC), neoadjuvant therapy increased the curative resection rate, disease-free survival, and overall survival. Up to 32% of patients with esophageal cancer show a pathological complete response after neoadjuvant therapy. However, the efficacy of neoadjuvant therapy varies among different patients. We aim to compare the differences in the characteristics of peripheral blood T lymphocyte subsets before and after neoadjuvant therapy in patients with different curative efficacy.
This study enrolled 269 ESCC patients who received neoadjuvant treatment followed by esophagectomy planned 4–6 weeks after preoperative therapy. The postoperative pathological results divided patients into the main pathological response (MPR) and non-MPR groups. Compare the differences in peripheral blood T lymphocyte subsets before neoadjuvant therapy, and analyze the trend of changes in T lymphocyte subsets before neoadjuvant therapy, before surgery, in the short term after surgery, and at the initial follow-up after surgery.
Before receiving neoadjuvant therapy, the peripheral blood CD4/CD8(p = 0.001) and helper T cell rate (THrate)(p = 0.006) in the MPR group were significantly higher than those in the non-MPR group. In contrast, the suppressor T cell rate(TSrate) was lower(p = 0.029) in the MPR group. After neoadjuvant therapy, the CD4/CD8 in both groups reached similar classes, but the THrate decreased dramatically and TSrate increased more in the MPR group. At the first follow-up after surgery, the peripheral blood CD4/CD8, THrate, and TSrate of both groups of patients tended to be at the same level.
T lymphocyte subsets in the peripheral blood significantly differed among patients with different neoadjuvant treatment efficacy. High levels of CD4/CD8, THrate, and low levels of TSrate before receiving neoadjuvant therapy may have better curative efficacy.